Cargando…
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
BACKGROUND: Approximately 30% of patients with epidermal growth factor receptor (EGFR)-activating mutations have no response to EGFR-tyrosine kinase inhibitors (TKIs) (primary resistance). However, little is known about the molecular mechanism involved in primary resistance to EGFR-TKIs in EGFR-muta...
Autores principales: | Zhang, Yang, Zeng, Yuanyuan, Liu, Ting, Du, Wenwen, Zhu, Jianjie, Liu, Zeyi, Huang, Jian-an |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647099/ https://www.ncbi.nlm.nih.gov/pubmed/31331328 http://dx.doi.org/10.1186/s12931-019-1137-4 |
Ejemplares similares
-
The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
por: Du, Wenwen, et al.
Publicado: (2020) -
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
por: Lian, Zengzhi, et al.
Publicado: (2020) -
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
por: Fu, Yulong, et al.
Publicado: (2020) -
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018) -
Influence of PD‐L1 expression on the efficacy of
EGFR‐TKIs in
EGFR
‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)